Aim: To study efficacy and safety of nebivolol in patients with stable angina pectoris.
Material: Twenty patients with stable effort angina pectoris and positive exercise test without contraindications to beta-blockers, signs of NYHA class III-IV heart failure, and obstructive lung disease. After 5-7 days of control period all patients were given nebivolol (starting dose 5 mg/day) for 8 weeks. Graded exercise tests on treadmill and patient's diaries were used for assessment of treatment efficacy.
Results: Treatment with nebivolol (5-10 mg o.d. ) was associated with significant slowing of heart rate, lowering of blood pressure, and increase of exercise duration until appearance of angina or 1 mm ST-segment depression. Nebivolol did not affect left ventricular ejection fraction, bronchial conductance, or results of biochemical tests (including lipid profile). Adverse reaction (dizziness which disappeared after lowering of a dose) was registered in 1 patient.
Conclusion: Nebivolol is an effective drug for the treatment of patients with stable angina.